Abstracts A201 employment than non-smokers or ex-smokers: 14.26% of subjects acknowledge having had their employment disrupted within the past 6 months.The differences noted between the "smokers", "ex smoker" and "non smoker" populations are statistically significant (P < 0.001) with prevalence of disrupted employment respectively of 19%, 15.25% and 11.57% (p < 0.01). It is also noted that the prevalence of smoking during work hours is significantly more important when the hierarchical superior smokes. 64.44% smoke during work hours if the hierarchical superior smokes, vs51.17% if the hierarchical superior does not smoke ( p < 0.004) CONCLUSIONS: In a population representative of persons at work on French soil, this study confirms the data collected abroad and in certain businesses in France. Therefore, the justification for taking smoking into account at the work place is reinforced by its health consequences as well as its direct consequences on the work produced.
RESPIRATORY-RELATED DISORDERS -Patient-Reported Outcomes Studies

PRS31 RELATIONSHIP BETWEEN DAILY DOSING FREQUENCY, COMPLIANCE, HEALTH CARE RESOURCE USE, AND COSTS: EVIDENCE FROM THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Toy EL 1 , Beaulieu NU 2 , McHale JM 2 , Welland TR 1 , Plauschinat C 3 , Swensen A 3 , Duh MS 2 1 Analysis Group, Lakewood, CO, USA, 2 Analysis Group, Boston, MA, USA, 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA OBJECTIVES: To assess the relationship between the daily dosing frequency (DDF) of COPD pharmacotherapies and treatment compliance; to estimate the effect of compliance on health care resource utilization (HCRU) and costs. METHODS: COPD patients were identified using a health insurance claims database covering 8 million lives (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . Patients were stratified based on the recommended DDF (QD, BID, TID, QID) of their first COPD drug claim post COPD diagnosis. Compliance was measured using proportion of days covered (PDC). HCRU outcomes included inpatient days and medical visits (inpatient, outpatient, and emergency room). A multivariate regression model assessed the relationship between compliance and one-year HCRU controlling for demographics, comorbidities, and baseline resource use. Unit health care costs were obtained from the 2005 Medical Expenditure Panel Survey data and adjusted to 2008 dollars. Total costs were modeled by multiplying unit costs by the observed HCRU. RESULTS: Sample sizes ranged from 3,678 (QD) to 25,011 (BID). Compliance was strongly correlated with DDF: PDC over one year for QD, BID, TID, and QID patients was 43%, 37%, 30%, and 23%, respectively (all p < 0.001 vs. QD). Multivariate analysis showed that one-year compliance was correlated with HCRU. For 1,000 COPD patients, a 5 percentage point increase in PDC reduced the number of inpatient visits by 2.5%, hospital inpatient days by 3.1%, and emergency room visits by 1.8%; the estimated number of outpatient visits increased by 0.2% (p < 0.001 for all comparisons). This increase in compliance yielded approximately $300,000 in cost savings from decreased HCRU. CONCLUSIONS: COPD patients who initiated treatment with QD dosing had significantly higher compliance than those with more frequent dosings. Patients with higher compliance were found to incur fewer hospital-and emergency room-related visits. In a hypothetical cohort of 1,000 COPD patients, increasing PDC by 5 percentage points would save $300,000 per year, mostly from reduced hospital visits.
PRS32
RELATIONSHIP OF COST-SHARING LEVELS TO ADHERENCE WITH DUAL-CONTROLLER THERAPY AMONG ASTHMA PATIENTS
Vaidya V 1 , Hong SH 2 , White-Means S 2 , Gourley D 3 1 University of Toledo, Toledo, OH, USA, 2 University of Tennessee Health Science Center, Memphis, TN, USA, 3 University of Tennessee, Memphis, TN, USA OBJECTIVES: To analyze the effect of cost-sharing levels and other co-variates on adherence to asthma controller therapy among patients with moderate persistent asthma. METHODS: Data for this study came from a large administrative claims dataset (MarketScan). The selection criteria for this study included patients with at least one asthma-related outpatient claim (ICD-9-CM 493.XX).Asthma patients on dual controller therapy (ICS and LABA or ICS and LTRA) were identified and the initial date of LABA or LTRA prescription served as the index date.Patients were required to be continuously enrolled during the entire study period. The medication possession ratio (MPR) was used to measure adherence. RESULTS: A total of 1,447 patients met the study criteria. Of these patients, 898 (62.1%) were initiated on ICS+LABA, and 549 (37.9%) were initiated on ICS+LTRA. The average combined adherence to controller regimen was 0.45 (median = 0.43) for the entire study population.The odds of having increased adherence (MPR above the median) decreased significantly with the increase in cost-sharing levels. Compared with patients having $0-15 cost-sharing level, patients having $16-30 (odds ratio [OR] = 0.449, 95% CI = 0.312-0.616 ), $31-45 (OR = 0.246, 95% CI = 0.168-0.358) and $46 and more (OR = 0.131, 95% CI = 0.084-0.206) had lower odds of having appropriate adherence. Type of insurance plan, geographical region, and type of controller therapy were also significantly associated with adherence. CONCLUSIONS: Even though the need to be adherent is greater among patients on dual-controller therapy, cost-sharing levels played an important role in level of adherence. The study also found the type of controller medication to be associated with the adherence to the therapy.
PRS33 TRANSLATING THE EXACT: ENSURING CONCEPTUAL EQUIVALENCE ACROSS MULTIPLE CULTURES
Arnold BJ 1 , Murray L 2 , Herzberg T 1 , Roberts L 2 , Leidy N 2 1 FACIT.org Translations, Elmhurst, IL, USA, 2 United BioSource Corporation, Bethesda, MD, USA OBJECTIVES: Translation and linguistic validation of patient reported outcomes (PRO) measures is an essential component of research methodology in preparation for multinational clinical trials. The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) was designed to evaluate frequency, severity, and duration of acute exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis. The EXACT is 14-item daily diary designed to be administered on an electronic handheld device (e.g. personal digital assistant (PDA)). The objective of this work was to translate and linguistically validate the EXACT for use in 17 countries: Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Hungary, Japan, Korea, The Netherlands, Peru, Philippines, Poland, Romania, South Africa, Taiwan and UK. METHODS: The EXACT was translated according to industry standard methodology, including detailed item definitions based on qualitative work conducted during instrument development. Five patients per country completed the respective translated questionnaire and participated in a cognitive interview. Interviews were conducted using a standardized guide to assess the understandability, cultural relevance, and appropriateness of wording of the translations. Qualitative analyses were performed to ensure that the content validity of the EXACT was maintained and equivalent across language versions. RESULTS: The study sample consisted of 90 patients with COPD (57.7% male). Mean age was 63 years. The sample consisted of patients who speak 14 languages collectively. All EXACT translations were well understood and proved relevant to the patients in this sample. Of interest, terms such as, "chest feel tight", and "short of breath" were understood and described similarly by participants across countries. CONCLUSIONS: The results indicate the EXACT translations were conceptually equivalent to the English source version and easily understood by the target population for all 17 countries. We consider these translations acceptable for PRO assessment in international research and clinical trials, bringing the total number of validated EXACT translations to 25.
PRS34 EVALUATING PEOPLE'S PREFERENCES FOR PREVENTIVE TREATMENT OF LATENT TUBERCULOSIS INFECTION USING A DISCRETE CHOICE EXPERIMENT
Guo N 1 , Marra F 1 , Marra C 1 , Elwood K 2 , FitzGerald M 1 1 University of British Columbia, Vancouver, BC, Canada, 2 British Columbia Center for Disease Control, Vancouver, BC, Canada OBJECTIVES: This study aimed to quantify the preferences of people with latent tuberculosis infection (LTBI) when making decisions on whether to accept preventive treatment with Isoniazid and to understand the trade-off nature of their decisionmaking. METHODS: English-speaking adults with LTBI were recruited from the tuberculosis (TB) clinic at British Columbia Centre for Disease Control. A customdesigned discrete choice experiment (DCE) measured preferences for 6 attributes of preventive treatment decision-making. A conditional logit model was performed to estimate respondents' preferences. RESULTS: Among the 152 participants, 142 (93.4%) with valid DCE responses were included for data analyses. Their average age was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of the preventive treatment (Risk of developing active TB after treatment, −0.23, p < 0.001), Risk of developing liver damage (−0.16, p < 0.001), Length of treatment (−0.05, p < 0.001), Risk of developing skin rash (−0.03, p = 0.002), and Risk of developing fatigue (−0.03, p = 0.009) were significant determinants of respondents' choices of preventive treatment. The negative preference estimates revealed that respondents were averse to higher risk of developing active TB, higher risk of developing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of clinic visit was not a significant factor. Respondents' preferences varied according to their socio-demographic characteristics, past experiences of TB, BCG vaccination status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest that respondents were consistently in favor of LTBI preventive treatment with higher effectiveness, less side effects and shorter length. Current cigarette smokers, motivated to quit smoking, participated in the trial and completed the MNWS instrument. Descriptive statistics (mean ± standard error) of the MNWS scores from weeks 2 to 7 were computed. Time-course comparisons stratified by PVR were performed, with weekly responders defined by PVR = 0 and nonresponders otherwise. Multivariate repeated-measures mixed-effects regression was conducted for each MNWS domain score as the outcome variable. Covariates included baseline, treatment, patient characteristics, smoking history and PVR. Statistical significance was reached when two-sided p ≤ 0.05. RESULTS: The mean baseline MNWS scores of varenicline vs. NRT were comparable. By PVR, varenicline significantly reduced the mean urge to smoke vs. NRT in weeks 2, 3, 4 and 5 (0.45 ± 0.10; 0.28 ± 0.09; 0.27 ± 0.10; 0.27 ± 0.09, respectively; all p < 0.01) among responders, and in weeks 2 to 6 (0.59 ± 0.13; 0.44 ± 0.14; 0.46 ± 0.16; 0.52 ± 0.18; 0.38 ± 0.17; all p < 0.03) among non-responders. The mean negative affect scores were significantly lower in weeks 2 to 5 and 7 (0.31 ± 0.07; 0.20 ± 0.06; 0.18 ± 0.07; 0.23 ± 0.07; 0.13 ± 0.06; all p < 0.03) among responders and in week 2 (0.22 ± 0.11; p < 0.04) among non-responders. Additionally, restlessness was significantly reduced in weeks 2 to 5 (0.45 ± 0.10; 0.33 ± 0.09; 0.22 ± 0.09; 0.22 ± 0.08; all p < 0.02) among responders and in week 2 (0.42 ± 0.14; p < 0.003) among non-responders, and similarly the reduction of increased appetite (0.38 ± 0.18; p < 0.05) among nonresponders in week 7. CONCLUSIONS: Overall, lower mean patient-reported MNWS scores associated with symptoms of tobacco withdrawal were observed for varenicline than for NRT, reaching statistical significance, particularly among abstainers. Differences in the dynamics of treatment effects along with concomitant abstinence status warrant further bivariate analyses.
RESPIRATORY-RELATED DISORDERS -Health Care Use & Policy Studies
PRS36 NEED FOR IMPROVING ACCESS TO ESSENTIAL MEDICINES AND TREATMENT BEHAVIOUR TO BRONCHIAL ASTHMA A CHRONIC DISEASE Kotwani A
Vallabhbhai Patel Chest Institute, Univ of Delhi, Delhi, India OBJECTIVES: It is expected that chronic diseases will account for 73% of deaths and 60% of the global diseases by 2020. India is experiencing a fast health transition, in 2005 chronic disease contributed to an estimated 53% of deaths and 44% of disability-adjusted life years lost. Chronic diseases are a serious public health issue, particularly because they require long-term therapy. Asthma, a major chronic disease, has become a cause of global concern in terms of its increasing prevalence, morbidity, and economic impact. Improving access to essential medicines and adherence to standard treatment guidelines can decrease the morbidity and mortality. The present scenario of access to essential medicines and treatment behaviour to asthma in India is investigated. METHODS: Recent studies conducted (2007-2009) on asthma management and adherence to therapy were analysed. Data on availability and price of two essential medicines for asthma, beclomethasone and salbutamol inhalers was collated from five medicine price studies conducted in five states of India, Haryana, Karnataka, Maharashtra, Rajasthan and Chennai (capital, Tamil Nadu state). RESULTS: Except for Rajasthan no inhalers were on state essential medicine list and were not available in any of the public facility; in Rajasthan these inhalers were available only in public facility of capital city. Results of the asthma management studies indicate poor knowledge regarding treatment of bronchial asthma by prescribers, pharmacists and by patients and asthma is not treated according to standard treatment guidelines. More than 80% patients and/or prescribers are treating acute episodes, rather than focusing on long-term asthma control. Ninety-two percent of patients alter the dose of inhaled corticosteroids after the acute attack. CONCLUSIONS: Since the incidence of chronic diseases are increasing rapidly in India, there is urgent need for improving access to essential medicines, treatment guidelines, policy making, patient & provider education, and resource allocation for chronic diseases, like bronchial asthma.
PRS37 DRUG UTILIZATION PATTERNS FOR PEDIATRIC ASTHMA IN AMBULATORY CARE SETTINGS
Yang M, Patel A, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: This study examined the asthma medications prescribing patterns among pediatric asthma visits in ambulatory care settings in the United States. METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical Care Survey (NAMCS) and the outpatient data of the National Hospital Ambulatory Medical Care Survey (NHAMCS) of year 2006-2007 was conducted involving children aged less than 18 years and diagnosed with asthma (ICD-9-CM 493.XX). The analyses focused on medications based on the guidelines of the National Asthma Education and Prevention Program (NAEPP). Descriptive statistics was used to examine the prescribing pattern. RESULTS: According to NAMCS and NHAMCS, there were18 million (0.87%) physician office visits by children with asthma. Long Acting β2 Agonist was highly prescribed among (57.50%) office visits, followed by Leukotrine Modifiers (29.91%) and Inhaled Corticosteroids (27.88%). Oral Corticosteroids and Short Acting β2 Agonist were prescribed in 15.99%, and 14.18% of office visits, respectively. In terms of individual medicines, Albuterol, was mostly prescribed among 10.43 million visits, followed by Montelukast, 5.42 million visits. Prednisolone was prescribed in 2.71 million visits and Levalbuterol was prescribed in 2.36 million visits. CONCLUSIONS: Long Acting β2 Agonist and Leukotrine Modifiers was the most highly prescribed medication class and Albuterol and Montelukast were highly prescribed individual medications in pediatrics asthma ambulatory care visits in the United States.
PRS38 DRUG PRESCRIBING PATTERN IN AMBULATORY CARE SETTINGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006-2007
Parikh R, Mehta H, Patel J, Aparasu R University of Houston, Houston, TX, USA OBJECTIVES: To examine the prescribing pattern of drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in ambulatory care visits and to assess the variation in the prescription of first line of therapy across sex, race and geographic region. METHODS: Data of 2006-2007 National Ambulatory Medical Care Survey (NAMCS) and outpatient files of National Hospital Ambulatory Medical Care Survey (NHAMCS) were analyzed. Sample data was weighted to provide US national estimates. Adults more than 25 years of age were included in the study and COPD visits were identified (ICD-9-CM: 491,492,496). First line of therapy was defined as prescription of either beta-agonist or anticholinergics. Descriptive weighted analysis was performed to examine the prescribing pattern of drugs and multivariate logistic regression using complex survey design was conducted to identify variation for first line of therapy across sex, race and region, while controlling for age, tobacco use, insurance, metropolitan area, and region. RESULTS: In 2006-2007, COPD accounted for 70.25 million (95% CI: 60.69-79.81) ambulatory care visits by adult patients, representing 3.3% of the total ambulatory visits. Of these visits, majority were made by females (59.14%), whites (87.31%) and living in the southern region (44.78%). COPD medications were only prescribed in 42.13% of the visits. Highly prescribed medications were bronchodilators (34.33%), followed by combination therapy (9.66%) and inhaled corticosteroids (2.71%). First line of therapy was prescribed at 25.17% (95% CI: 21.62-28.72) visits: 19.16% visits received beta-agonist and 11.84% visits received anticholinergics. No variation was found across sex, race, and region for the prescription of first line of therapy for COPD. CONCLU-SIONS: Bronchodilators were highly prescribed medication for COPD in outpatient visits. The first line of therapy did not vary significantly across sex, race and region for COPD.
PRS39 ASSESSING DEMOGRAPHIC DISPARITIES IN UTILIZATION OF INHALED CORTICOSTEROIDS AMONG PATIENTS WITH PERSISTENT ASTHMA
Vaidya V, Partha G, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: To find out demographic factors predicting inhaled corticosteroid utilization among asthma patients. METHODS: The study utilized data from the four-state sample of National Asthma Survey (NAS), sponsored by the National Center for Environmental Health (NCEH), Centers for Disease Control. The study population consisted of patients with persistent asthma as (defined by the symptoms score based on NHLBI guidelines). Frequency distributions were made to characterize the study population. Logistic regression was carried out to determine the odds of reporting use of inhaled corticosteroids across various demographic variables (Age, gender, race, income level, insurance coverage, and disease severity). Data was analyzed using SAS v9.0. RESULTS: Underutilization of inhaled corticosteroids (ICSs) was found to exist in the asthmatic patients as over half of our study population (52.6%,n = 323)did not even report the use of ICSs. Disparities were also found to exist in our study across various variables. Blacks were found to have much lower odds of using ICSs when compared to other races (OR,0.572;CI,0.566-0.579). Black uninsured children also demonstrated similar trends. Patients having some form of
